Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Dec;10(6):893-895.
doi: 10.21037/hbsn-21-412.

Systemic treatment of hepatocellular carcinoma: the times they are a-changin'

Claudia Campani  1   2   3 , Jean-Charles Nault  1   2   4   5
Affiliations
Editorial

Systemic treatment of hepatocellular carcinoma: the times they are a-changin'

Claudia Campani et al. Hepatobiliary Surg Nutr. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/hbsn-21-412). The authors have no conflicts of interest to declare.

Comment on

References

    1. Bruix J, Chan SL, Galle PR, et al. Systemic treatment of hepatocellular carcinoma: An EASL position paper. J Hepatol 2021;75:960-74. 10.1016/j.jhep.2021.07.004 - DOI - PubMed
    1. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020;382:1894-905. 10.1056/NEJMoa1915745 - DOI - PubMed
    1. Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol 2021;22:977-90. 10.1016/S1470-2045(21)00252-7 - DOI - PubMed
    1. Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology 2017;153:812-26. 10.1053/j.gastro.2017.06.007 - DOI - PMC - PubMed
    1. Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 2018;15:325-40. 10.1038/nrclinonc.2018.29 - DOI - PMC - PubMed